ArticleTranslational cancer research2026
ZNF460 inhibits HMGCL and promotes PI3K pathway in colon cancer.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Zinc finger protein 460 (ZNF460) is highly expressed in colon cancer, but its specific mechanism of action and downstream targets have not yet been clarified. Therefore, this study aimed to investigate the expression pattern, prognostic value, and biological function of ZNF460 in colorectal cancer (CRC), and to elucidate its underlying molecular mechanisms. Methods: Cell Counting Kit-8 (CCK-8) assay, 5-ethynyl-2'-deoxyuridine (EdU) assay, and Western blot assays were used to investigate the biological function of ZNF460 in CRC. Transcriptomic and clinical data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) were analyzed to assess ZNF460 expression, prognostic value, and clinical relevance. Functional enrichment, nomogram construction, single-cell sequencing, cell communication, and pseudotime analyses were conducted using R packages including seurat, cluster profiler, cell chat, and monocle 2. Statistical significance was set at P<0.05, with appropriate tests applied based on data type. Results: ZNF460 expression was upregulated in colon cancer. High expression of ZNF460 was associated with poor clinical stage and prognosis of patients. Cell experiments revealed the role of ZNF460 in promoting colon cancer cell proliferation. Single-cell sequencing revealed that ZNF460 had close interactions with malignant, plasma, endothelial, myofibroblasts and other cells. Bioinformatics analysis and Conclusions: ZNF460 is highly expressed in CRC and is associated with poor prognosis. ZNF460 promotes cancer cell proliferation and participates in tumor cell communication. Mechanistically, ZNF460 activates the PI3K pathway by inhibiting HMGCL expression, thereby promoting the progression of CRC, suggesting that it is a potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.